OBJECTIVE: Obesity is frequently associated with insulin resistance, dyslipidemia, hypertension and an increased risk of cardiovascular disease, reflected in elevated markers of inflammation, in particular C-reactive protein (CRP). To what extent the insulin resistance or the obesity per se contributes to increased CRP levels is unclear. In morbidly obese patients, gastric bypass surgery causes marked changes in body weight and improves metabolism, thereby providing informative material for studies on the regulation of inflammatory markers. DESIGN: Prospective, surgical intervention study of inflammatory markers in morbidly obese subjects. SUBJECTS: In total, 66 obese subjects with mean age 39 y and mean body mass index (BMI) 45 kg/m 2 were studied prior to and 6 and 12 months following Roux-en-Y gastric bypass (RYGBP) surgery. MEASUREMENTS: Serum concentrations of high sensitivity CRP, serum amyloid A (SAA) and interleukin-6 (IL-6), as well as markers of glucose and lipid metabolism. RESULTS: Prior to surgery, CRP levels were elevated compared to the reference range of healthy, normal-weight subjects. CRP correlated with insulin sensitivity, as reflected by the homeostatic model assessment (HOMA) index, but not BMI, when corrected for age and gender. Surgery reduced BMI from 45 to 31 kg/m 2 and lowered CRP, SAA and IL-6 levels by 82, 57 and 50%, respectively, at 12 months. The reduction in CRP was inversely related to HOMA at baseline independently of the change in body weight (r ¼ À0.36, P ¼ 0.005). At 12 months, 140 and 40% reductions in CRP were seen in subjects with HOMA o 4 (insulin sensitive) and HOMA49 (insulin resistant) despite similar reductions in BMI. Reductions in SAA and IL-6 tended to parallel the changes in CRP, but were less informative. CONCLUSION: In morbidly obese subjects, gastric bypass surgery lowers energy intake, reduces inflammatory markers and improves insulin sensitivity. Despite a marked reduction in body weight, only a small effect on CRP levels was seen in insulinresistant patients, indicating that flexibility of circulating CRP levels is primarily dependent upon insulin sensitivity rather than energy supply.
Introduction
Obesity is associated with increased morbidity and mortality due to a greater risk of developing cardiovascular disease, [1] [2] [3] and type 2 diabetes, due at least in part to the development of insulin resistance. 3 Obese subjects have elevated circulating concentrations of inflammatory markers from the liver, including C-reactive protein (CRP), fibrinogen and serum amyloid A (SAA). Obesity is also associated with immune dysfunction 1, 4 and elevated levels of proinflammatory cytokines such as interleukin-6 (IL-6) and tumour necrosis factor-a (TNF-a), which stimulate hepatocytes to produce acute-phase proteins. 5 Cytokines are not only produced by inflammatory cells in damaged tissues but are also secreted from adipocytes, 6 making obesity a confounding factor in the association between acute-phase proteins and cardiovascular disease. 7, 8 There are diverging reports regarding the importance of obesity per se and insulin resistance for driving the increase in inflammatory markers. In a study of CRP, IL-6 and TNF-a in healthy women and women with polycystic ovary syndrome, obesity and not insulin resistance was found to be the major determinant of the inflammatory markers. 9 In contrast, in a study of obese women in which CRP was measured before and after 3 months of reduced energy intake, the relation between CRP concentrations and insulin resistance appeared independent of obesity. 10 The medical treatment of obesity, in particular morbid obesity (BMI Z40 kg/m 2 ), is unsatisfactory and has led to the increased use of surgery worldwide. 11 Roux-en-Y gastric bypass (RYGBP) causes a marked reduction in adipose tissue mass, 12 alters adipose tissue regulatory hormones 13 and reduces morbidity. 14 The changes in body weight and metabolic balance provide a useful study group from which we can examine interactions between obesity, insulin resistance (as indicated by a high HOMA index; ie. impaired fasting insulin sensitivity) and inflammatory markers with reference to beneficial effects of surgical weight loss on morbidity.
Methods
Potential subjects were recruited from the obesity program register at Samariterhemmet Hospital in Uppsala, Sweden. Their written informed consent was obtained. The study group consisted of 66 morbidly obese patients planned for RYGBP: 12 men and 54 women with mean age 39 y (range 24-50), mean weight 127 kg (range 96-195) and mean BMI of 45 kg/m 2 (range 33-64). All patients had made previous attempts at weight loss. Some patients had also undergone prior surgical therapy for obesity; three had adjustable gastric banding and five had vertical-banded gastroplasty. Two of the patients were on medical treatment for type 2 diabetes, one received metformin and the other glipizide and insulin. The patients underwent RYGBP at the Department of Surgery, University Hospital, Uppsala. A small proximal gastric pouch (15 ml) was created along the lesser curvature and totally separated from the main stomach by cutting linear staplers. The small bowel was divided 20 cm distal to the ligament of Treitz and a Roux-limb, at least 50 cm long, was made. The Roux-limb was placed retrocolic, retrogastric and anastomosed to the small gastric pouch directly below the oesophagus. The small bowel continuity was maintained by a linearly stapled side-to-side entero-enterostomy. 5 The procedure excludes the stomach and duodenum from the passage of food and is believed to have both restrictive and malnutritive components. At preoperative assessment, blood was taken after an overnight fast, and body height and weight were measured to determine the BMI. Sera were prepared and stored at À701C until analysis. At 6 and 12 month postoperative consultations, these same procedures were performed. CRP was analysed in serum with latex enhanced reagent (N Latex CRP, Dade Behring, Deerfield, IL, USA) using a Behring BN ProSpec immunonephelometer. Monoclonal antibodies to CRP are coated in polystyrene particles, which agglutinate when mixed with human serum samples containing CRP. The CRP concentration in the sample is reflected by the intensity of scattered light in the nephelometer. The intraassay coefficient of variation (CV) of the CRP method was 1.4% at both 1.23 and 5.49 mg/l and the detection limit was 0.16 mg/l. SAA levels were determined in serum with a latex enhanced reagent (N Latex SAA, Dade Behring, Deerfield, IL, USA) and a Behring BN ProSpec analyser. The intra-assay CV of the SAA method was 5.9% at 12.8 mg/l and 3.2% at 81.7 mg/l. The limit of detection was 0.74 mg/l. Serum IL-6 levels were analysed with the Quantikine HS IL-6 ELISA kit (HS600B, R&D Systems, Minneapolis, MN, USA). IL-6 from the standards and samples bind to the specific, immobilised monoclonal antibodies precoated on microtiter plates during the first incubation. Enzyme-linked polyclonal antibodies are then added prior to the second incubation, after which substrate and amplifier solutions are used to achieve colour development as measured by photospectrometry. The limit of detection was 0.15 ng/l. The total CV of the method was 7% and interassay CV was 5%. Fasting plasma glucose, total cholesterol, LDL-cholesterol, HDL-cholesterol, triglycerides (TG) and free fatty acids (FFA) were measured with routine clinical chemistry laboratory techniques and insulin with an AutoDELFIA automatic immunoassay system (Wallac Oy, Turku, Finland), at University Hospital Uppsala, Sweden.
Data are given as means and standards deviations (s.d.) or median with total range, while skewed data were transformed logarithmically. Factorial ANOVA and ANCOVA were used to evaluate differences between groups, while the paired t-test was used to calculate effects of surgery. Linear correlation analysis was used to evaluate relationships, after logarithmic transformations, between CRP, HOMA, SAA and IL-6. The level of significance was taken at Po0.05. To illustrate the relationship between insulin resistance and changes in CRP, the subjects were divided into three groups; HOMA o4 (n ¼ 28), HOMA 4-9 (n ¼ 24) and HOMA 49 (n ¼ 9), with respective baseline BMI values of 46.4 (77.4), 42.7 (74.9) and 46.4 (76.9) kg/m 2 . The HOMA index was calculated by multiplying fasting plasma glucose and fasting serum insulin and then dividing by 22.5. 15 Calculated from a study of healthy individuals given an euglycemic, hyperinsulinemic clamp, a mean value of insulin-mediated glucose uptake of 4.2 mg/kg/min (mean -2 s.d.) or above was considered normal insulin sensitivity and corresponded to HOMA o 4, while HOMA 49 identified individuals with pronounced insulin resistance (o2 mg/kg/min at clamp). 16 
Results
Inflammatory markers and metabolic parameters prior to and after RYGBP surgery The morbidly obese patients had altered lipid and glucose metabolism, and elevated levels of inflammatory markers, as compared to the reference range of healthy normal-weight subjects (Table 1) . Postoperatively, the subjects decreased in weight by 28 kg (22%) at 6 months and by 38 kg (30%) at 12 months. All the inflammatory marker levels lowered after surgery. The mean reductions at 6 and 12 months were 57 and 82% for CRP, 43 and 57% for SAA, and 30 and 50% for CRP reduction following gastric bypass surgery C Holdstock et al IL-6, respectively (Table 1) . Glucose, insulin, triglycerides, cholesterol and LDL-cholesterol were decreased at 6 months and at 1 y. HDL-cholesterol had increased by 12 months.
Relationships between variables
At baseline, CRP correlated directly with BMI and HOMA index (Figure 1) , and BMI and HOMA index were related (r ¼ 0.35, P ¼ 0.004). In multivariate analysis with BMI, HOMA index, age and sex as independent variables, the dependent variable CRP was related to HOMA index and to some extent gender (Table 2) . Postoperatively, the change in HOMA correlated inversely with baseline HOMA (r ¼ 0.32, Po0.01) and positively with the change in BMI (r ¼ 0.34, Po0.008). CRP concentrations showed strong correlations with both SAA (r ¼ 0.70, Po0.0001) and IL-6 (r ¼ 0.51, Po0.0001) at baseline (Figure 2 ), as well as postoperatively.
The reduction in CRP seen postoperatively was inversely related to HOMA at baseline, that is, the relative change in CRP following surgery was smallest in subjects with the highest HOMA index values, indicative of insulin resistance (Figure 3) . The association between the change in CRP and HOMA index at baseline was seen independently of the change in body weight and baseline CRP levels. When the study sample was divided into three groups according to HOMA indices (o4, 4-9 and 49), the most pronounced reduction in CRP was seen in the insulin-sensitive group (HOMA o4) and the poorest responders were in the insulinresistant group (HOMA 49), despite a similar relative change in BMI in all three groups (Figure 4 ). HOMA improved in each group from insulin sensitive to resistant by 56, 71 and 79%, respectively. Significant differences (Po0.01) between groups for the change in CRP was found but not for BMI. The reduction postoperatively in IL-6, but not SAA, correlated negatively with HOMA (r ¼ 0.27, P ¼ 0.047).
Discussion
In this prospective study, we took advantage of a large study sample comprised of severely obese individuals and examined the effect of surgically induced weight loss on inflammatory markers and metabolism. We observed that the reduction in CRP following surgery, but not the changes in body weight, fatty acids or triglycerides, was related to insulin resistance, reflected by a high HOMA index that denotes impaired fasting insulin sensitivity. This indicates that circulating levels of CRP are regulated with greatest flexibility in insulin-sensitive subjects, who may therefore CRP reduction following gastric bypass surgery C Holdstock et al gain more from surgical weight loss in terms of reducing inflammatory marker levels, than insulin-resistant individuals.
CRP is currently the most widely measured acute-phase protein of inflammation. The circulating concentrations are low in healthy people without acute illness and with the high-sensitivity techniques available today, even low levels are predictive for future cardiovascular events including myocardial infarct and stroke. 2, [17] [18] [19] As mentioned, there are diverging reports regarding the roles of obesity and insulin resistance in influencing the production of CRP. The circulating levels are elevated in obesity, 8, 20 particularly when adipose tissue is centrally deposited, 2 as indicated by a high waist-hip ratio. 7, 21 The levels correlate positively with body fat in nondiabetic Pima Indians 22 and are high in people with type 2 diabetes. [23] [24] [25] In a recent study of the polycystic ovary syndrome, obesity was reported to be the major determinant in driving the production of markers CRP, IL-6, and tumour necrosis factor. 9 Others found that CRP, in addition to BMI, 26 also correlated with the metabolic syndrome as indicated by insulin resistance, obesity, hypertension, impaired glucose tolerance, low HDL-cholesterol and hypertriglyceridaemia. 26 Similarly, the risk of developing type 2 diabetes in lean and overweight women could be explained by the strong correlation between CRP and fasting hyperinsulinaemia, 27 as CRP correlated independently with insulin sensitivity in healthy non-diabetic subjects. 28 Furthermore, the increase in CRP and other inflammatory markers, such as IL-6, was not fully explained by BMI in impaired glucose tolerance and type 2 diabetes.
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The acute-phase protein SAA correlates positively with obesity 8 and is higher in people with type 2 diabetes mellitus and impaired glucose tolerance than in non-diabetic controls. 23, 29 Male subjects with coronary heart disease (CHD) have markedly higher SAA levels than those without CHD 30 and SAA may, due to its interaction with HDL-cholesterol, be a factor in the accelerated atherosclerosis of diabetes. 23 The finding of SAA in atherosclerotic plaques supports a link between inflammation, lipoprotein metabolism and the development of atherosclerosis. 31 The glycoprotein IL-6 is secreted from numerous cell types, including activated macrophages, monocytes, endothelium, 32 and adipocytes, from which approximately one-third of the serum concentration is derived. 7 IL-6 stimulates the production of acutephase proteins in the liver, 18 as well as having other pro-and anti-inflammatory roles. 33 The levels increase with adiposity, in particular abdominal, 7, 34 and omental fat cells secrete 2-3 times more IL-6 than subcutaneous adipocytes. 35 In type 2 diabetes, IL-6 levels are higher than in age-matched controls, 23 and a study of aboriginal men and women showed IL-6 to be an independent predictor of CRP levels. 26 In accordance with several studies, we found close associations between CRP, SAA and IL-6. Following surgery, the changes in SAA and IL-6 tended to parallel the changes in CRP, but were of lesser magnitude. Weight loss programs for obesity lower CRP levels. 3, 10, 19, [36] [37] [38] A study of healthy premenopausal women who completed a 1-y weight loss programme achieved a minimum 10% loss of weight and a decrease in cytokine (IL-6 and TNF-a) produc- CRP reduction following gastric bypass surgery C Holdstock et al tion. 34 Medical treatment with sibutramine or orlistat for 6 months achieved a reduction in CRP despite less weight loss (2-5.4%). 39 A 3-month cardiac rehabilitation and exercise training programme for coronary heart disease sufferers resulted in a reduction in cardiovascular risk factors and CRP levels regardless of statin therapy or weight loss, 40 and a similar programme for 18 months, involving overweight or obese subjects above 60 y of age, showed a decrease in CRP, IL-6 and TNF-a levels. 36 Likewise, surgically induced weight loss through gastric banding 4,41 lowered CRP to within the normal range. 41 However, other components of the insulin resistance syndrome did not return to normal. A recent examination of 37 subjects subjected to vertical-ring gastroplasty showed baseline relationships between CRP and IL-6 with HOMA. Postoperatively, the reductions in BMI and CRP were related while improvement of insulin sensitivity related to IL-6.
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To our knowledge, there are no previous reports on inflammatory markers following RYGBP surgery. In the present study, the decrease in CRP related to baseline insulin resistance independent of subsequent weight loss. This indicates that insulin sensitivity has a greater influence on circulating CRP concentrations than the actual degree of overweight. Furthermore, insulin-resistant individuals (HOMA49) experienced the smallest reduction in CRP compared with a greater decrease in insulin-sensitive subjects. The importance of insulin sensitivity rather than body weight is supported by observations of CRP changes in patients receiving various treatments during which body weight was not affected. Metformin for women with polycystic ovary syndrome lowered CRP concentrations without a change in body weight, 43 the result of which also occurred with lipid-lowering statin regimens. 30, 44 In contrast, oestrogen supplementation for postmenopausal women increased CRP but did not affect body weight. 45 Furthermore, the PPAR-agonist rosiglitazone lowered CRP and improved insulin sensitivity, whilst augmenting body weight. 46 In conclusion, the results of the present study indicate that in morbid obesity the factors inducing insulin resistance, rather than obesity per se, elevate the basal production of CRP. The reduction in CRP following gastric bypass is most pronounced in insulin-sensitive subjects, who thereby, in this respect, gain more from surgical weight loss than insulin-resistant individuals. This latter group, likely of having the largest risk of cardiovascular disease, should therefore be considered for additional measures, including exercise and pharmacological treatment, in order to fully benefit from RYGBP surgery. CRP reduction following gastric bypass surgery C Holdstock et al
